All posts by imreal

Benjamin Cravatt, Ph.D. Joins Ivy Brain Tumor Center’s Scientific Advisory Board


Dr. Benjamin Cravatt, a world-renowned chemical biologist

Dr. Benjamin Cravatt, a global leader in drug discovery and world-renowned chemical biologist

“I am looking forward to working with the Ivy Brain Tumor Center and helping them as they expand their Phase 0 clinical trials program to identify new, effective therapies for this underserved patient population,” said Dr. Cravatt.

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program which specializes in identifying new, first-in-class therapeutic agents that match the individual biologies of brain tumor patients, has announced the appointment of Benjamin Cravatt, Ph.D. to its Scientific Advisory Board. Dr. Cravatt is a world-renowned chemical biologist with extensive experience in drug discovery and drug development.

Dr. Cravatt is the co-founder of Vividion Therapeutics, Abide Therapeutics (acquired by Lundbeck Pharmaceuticals) and ActivX Biosciences (acquired by Kyorin Pharmaceuticals). He currently serves as Professor and Gilula Chair of Chemical Biology at Scripps Research. His numerous honors and accolades include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and the AACR Outstanding Achievement in Chemistry in Cancer Award.

“We are pleased to welcome Dr. Cravatt to our Scientific Advisory Board as we seek to redefine drug development for brain tumor patients,” said Dr. Nader Sanai, director of the Ivy Brain Tumor Center. “He is a widely respected global leader in drug discovery and has pioneered innovative strategies to identify and develop new therapies. His unique perspective and guidance will be invaluable as our clinical trials program enters its next phase of growth.”

More than 138,000 U.S. patients and 1.4 million patients worldwide are struggling with brain cancer. By the end of the year, another 256,000 will be diagnosed. For the most common malignant brain tumor – glioblastoma (GBM) – the average five-year survival rate is less than 5% and it’s been 20 years since a new drug approval has provided survival benefit.

“I am looking forward to working with the Ivy Brain Tumor Center and helping them as they expand their Phase 0 clinical trials program to identify new, effective therapies for this underserved patient population,” said Dr. Cravatt. “They are taking the proven principals of biotech and implementing them into academic science. It is a logical approach that no academic medical center or biotech has had the infrastructure to support.”

Current members of the Ivy Brain Tumor Center’s Scientific Advisory Board include Dr. Eric Holland of Fred Hutchinson Cancer Research Center, Dr. Frank McCormick of UCSF Helen Diller Family Comprehensive Cancer Center, Dr. Patricia LoRusso of Yale Cancer Center and Dr. Susan Chang of the UCSF Brain Tumor Center.

For more information about the Ivy Brain Tumor Center and its latest developments, please visit http://www.ivybraintumorcenter.org.

Share article on social media or email:

Azuna Launches New Non-Toxic Mold, Mildew and Odor Eliminator Air Cleaning and Refreshing Solutions


News Image

Azuna (http://www.AzunaFresh.com) today announces an expanded roster of natural, non-toxic mold, mildew and odor eliminating solutions that are ideal for use in a home, refrigerator, vehicles, workplace, boat, gym or dorm room – essentially anywhere there is air. Azuna debuted its original, Small Room Treatment air cleaning puck earlier this year to rave consumer reviews, and now adds a Large Room Treatment and a new odor-eradicating and cleansing All-Natural Spray to its offering, while additionally expanding the whole home kit and subscription options.

Azuna products are based on the properties of Australian tea tree oil, which is a proven anti-microbial and cleansing solution. Each Azuna puck is vented and contains gel that slowly evaporates over 60-90 days via natural air flow, simultaneously cleaning the surrounding air of mold, mildew, bacteria and odor. While the original 2 oz. puck ($14.99) will free a single room from irritants for up to three months, the new 8 oz. puck ($39.99) is ideal for larger spaces or for placement directly inside of home air vents. All Azuna pucks are refillable, with a Whole Home Kit ($99.99) containing 4-single room pucks and a 24 oz. refill pouch. Azuna is available in three light scents: Natural, Simply Citrus and Pure Vanilla, and is designed to eliminate odor instead of simply masking it. When used in a refrigerator, Azuna has also been proven to extend the shelf-life of stored fresh fruits and produce.

Additionally, Azuna today released its new 8 oz. pump All-Natural Spray ($14,99) which includes a proprietary blend of tea tree oil and other essential oils. The spray will eliminate odors, as well as clean, sanitize and neutralize surfaces against mold, mildew, fungus and bacteria. It is ideal for applications on everything from countertops to sneakers, sporting equipment, camping gear, clothing, vehicles or any surface that could use a refresh.

“We are committed to creating all-natural products that we can safely and gladly use around our children and pets in order to provide a healthy space for ourselves and our families to thrive,” said Azuna Founder and CEO, Scott Dancy. “Air that is free of mold, mildew and bacteria contributes to our overall wellness, and odor-free air contributes to our peace of mind. We love the feedback we have received from our customers and we are working on additional solutions that will make clean air easy to achieve in any space.”

Azuna offers consumers the opportunity to subscribe to receiving products at an additional discount, and ships free with every $35 purchase. Based in Buffalo, NY, Azuna is made in the USA and typically processes orders within one business day.

For more information, please visit Azuna’s Frequently Asked Questions: https://azunafresh.com/pages/frequently-asked-questions or follow Azuna on social media on Instagram or Facebook at @AzunaFresh.

ABOUT AZUNA

Azuna believes in keeping families healthy. As parents and pet owners who previously struggled with keeping homes clean and fresh, without subjecting loved ones to harmful chemicals, the Azuna team is dedicated to crafting solutions that can safely and naturally clean the air we breathe and the spaces we live in of mold, mildew, bacteria, fungus and odor. Azuna products utilize the unique properties of Australian tea tree oil, long proven to be nature’s effective antiseptic cleanser and preservative. Based in Buffalo, NY, Azuna products are made in the USA and can be found at http://www.AzunaFresh.com.

Share article on social media or email:

Longmont Dental Loft Announces Chief Calming Pawfficer is Returning


dog sitting on a patients lap

Bentley with a patient

He’s been extremely popular with our patients. In fact, in the past year we’ve had 3 patients adopt Australian Labradoodles as a result of meeting Bentley

After a hiatus due to COVID-19, Longmont Dental Loft’s therapy dog will be returning to the office effective June 29th, 2020. Bentley is an Australian Labradoodle with the title of Chief Calming Pawfficer. As the Chief Calming Pawfficer, Bentley interacts with patients that enjoy being around dogs. He typically sits on patients laps and is a comforting presence that makes patients feel at ease.

“Since we’ve been back from the COVID-19 closure, patients have asked us on a daily basis when Bentley is coming back,” said Adrienne Hedrick, Longmont Dental Loft Dentist, and owner. “He’s been extremely popular with our patients. In fact, in the past year we’ve had 3 patients adopt Australian Labradoodles as a result of meeting Bentley.”

During the past few months Bentley has been staying at home. He has had a lot of fun and has kept entertained by taking walks and playing with the vacuum cleaner. However, he misses seeing patients and is ready to go back to the office.

There will be several precautionary measures in place when Bentley is at the office. First, he will be in the office area away from patients unless a patient requests to see him. Second, before a patient encounters him, they will need to make sure they wash their hands. And Bentley won’t be at the office every day. If a patient wants to make sure he is available, Longmont Dental Loft is asking patients to request a visit with him in advance.

About Longmont Dental Loft

Longmont Dental Loft is a family friendly dental provider in Longmont, Colorado. Dr. Adrienne Hedrick and her team provide holistic, leading-edge dentistry to Longmont, Colorado residents who seek a trusted dental group with a practical approach that combines state of the art technology with education, efficiency, and genuine care. Services include everything from preventative care to full mouth rehabilitation. For additional information, visit http://www.longmontdentalloft.com

Share article on social media or email:

Mindbloom Launches Remote-Enabled Psychedelic Therapy In California To Meet Growing Demand


Mindbloom, a New York City-based consumer mental health and wellbeing company, has announced it will begin offering remote psychedelic therapy services to residents in the state of California this week. The company currently offers psychiatric clinician-supervised ketamine therapy to treat depression and anxiety to clients in New York, New Jersey, Nevada, Pennsylvania, and Florida with affordable and accessible pricing starting at $150 – $250 per session.

With headquarters on New York City’s Fifth Avenue, Mindbloom lifted its requirement for new clients to begin their journey with an in-person visit in March, converting to a full telehealth model in response to federal mandates for Americans to practice social distancing and limit unnecessary virus exposure.

Said Mindbloom Founder and CEO, Dylan Beynon, “As the COVID-19 pandemic escalates in the U.S., conditions for anxiety and depression have never been higher. Our partner clinicians have felt the call to service in this time of crisis. Our team has worked tirelessly to keep up with the demand for safe, accessible and affordable psychedelic medicine treatments.”

Using Mindbloom’s online platform, clients receive personalized, remotely-facilitated psychedelic therapy programs and ongoing virtual support from licensed psychiatric clinicians and trained guides. From initial video consultations to post-treatment 1:1 virtual integration sessions, Mindbloom clients are supported and supervised every step of the way.

How It Works:

  • Following an online survey to assess qualifying symptoms such as anxiety and depression, new clients consult with a licensed psychiatric clinician over video.
  • Ketamine tablets are prescribed and delivered to qualifying clients’ homes.
  • The first therapy session is scheduled; each session requires an in-person peer monitor to be present for the duration of the session.
  • A virtual provider prepares the client and peer monitor ahead of the session and remains available on-demand throughout the session.
  • Audioscapes and personalized psychedelic therapy content is available through Mindbloom’s web-based online platform to enhance the at-home experience.
  • Following each session, virtual providers are available to provide 1:1 integration support.

Said Mindbloom Medical Director Dr. Leonardo Vando, “We are fortunate to be in the position to accelerate the roll-out of our remote ketamine therapy programs in response to one of the greatest public health challenges Americans have ever faced.” He added, “Mindbloom began piloting remote treatment protocols several months prior to the onset of COVID-19, and we’ve safely and successfully facilitated over 500 remote sessions with overwhelmingly positive client outcomes.”

Mindbloom was established to increase Americans’ access to affordable, effective, and science-backed therapeutic experiences designed by leaders in the fields of psychiatry and psychedelic medicine. Founded by tech entrepreneur Dylan Beynon, designed by one of America’s foremost psychedelic medicine experts Dr. Casey Paleos, and clinically overseen by leading psychiatrist Dr. Leonardo Vando, Mindbloom’s initial offering is guided ketamine therapy affordably priced at $150 – $250 per session.

For more information about Mindbloom’s remote treatment options, safety precautions, or how to request a new client consultation, visit http://www.mindbloom.co

About Mindbloom, Inc.

Mindbloom is America’s leading destination for cutting-edge, science-backed approaches to achieving and maintaining optimal mental health and wellbeing through psychedelic medicine. Founded in New York City by seasoned tech entrepreneur Dylan Beynon, Mindbloom brings clinicians, researchers and technologists together to deliver guided ketamine therapy with supportive, thoughtfully designed, hospitality-inspired experiences. Treatment protocols are overseen by Medical Director and board certified psychiatrist Dr. Leonardo Vando and designed by Scientific Director Dr. Casey Paleos, a pioneer in psychedelic research and treatment. Mindbloom’s mission is to transform lives today to transform the world tomorrow by increasing access to transformational treatments that help its clients heal, grow, and expand their human potential.

Press Inquiries:

press@mindbloom.co

Share article on social media or email:

Valley-Wide Health has chosen WellRyde to improve quality of ridership across its multi-county service area throughout Southern Colorado


WellRyde

WellRyde

“We are excited to start our new transportation service with the tools offered by WellRyde software platform. WellRyde will offer our team the ability to effectively communicate, be efficient with our resources, and meet the needs of our clients and patients”, Jania Arnoldi, President/CEO, VWHS.

nuVizz Inc., today announced that Valley-Wide Health Systems, a Community / Migrant Health Center has chosen WellRyde to help facilitate trips across its network. Valley-Wide has thirteen primary healthcare delivery sites strategically located throughout multiple rural counties in Southern Colorado. These full-service clinics are complemented by eight dental clinics, four physical therapy clinics and numerous ancillary health services to address routine and/or complex needs of the patient population. Valley-Wide is offering this ride program to the patient populations and communities they serve to help them with their appointments, treatments, groceries, and other needs.

With this engagement, Valley-Wide will be able to provide high-quality, safe and integrated care services to the community. The WellRyde platform will enable call center personnel to book ride requests from the riders, provide robust scheduling and dispatch capability to the Transportation team, monitor progress of trips throughout the day and enable drivers to complete these Trips via a user-friendly App.

“We are honored to partner with Valley-Wide Health and enable them to provide quality care to their patient population and community they serve. With WellRyde platform, Valley-Wide can efficiently manage the trips for their riders, enable them to effectively utilize their fleet or drivers, monitor fleet real-time and expand to all locations fairly quickly”, said Veda Ramachandran, Vice President, Customer Success. “WellRyde features will also enable Valley-Wide to provide rich rider experience via reminder calls and SMS alerts thereby ensuring that they do not miss their appointments”.

According to Valley-Wide Health Systems President and CEO, Jania Arnoldi, “We are excited to start our new transportation service with the tools offered by the WellRyde software platform. WellRyde will offer our team the ability to effectively communicate, be efficient with our resources, and meet the needs of our clients and patients”.    

About VWHS

Valley-Wide Health Systems, a Community/Migrant Health Center (C/MHC), is a private non-profit 501 (c)(3) corporation governed by a volunteer community board. Established in 1976, Valley-Wide has thirteen primary health care delivery sites strategically located throughout multiple rural counties in Southern Colorado. These full-service clinics are complemented by eight dental clinics, four physical therapy clinics, and numerous ancillary health services to address routine and/or complex needs of the patient populations and communities served. Valley-Wide serves all ages through a family practice focus approach. Emphasis is placed on assisting the patient, reducing barriers such as cost, culture, language, literacy, and transportation that may hinder use of appropriate health care services.

About nuVizz, Inc.

nuVizz, Inc. (http://www.nuvizz.com) is a leading network-based last mile delivery & transportation management and customer experience SaaS platform.

WellRyde, a nuVizz Transportation solution, is an award-winning network-based delivery & transportation platform. Our mission is to provide a human transportation cloud by leveraging technologies, transportation fleet and rider demand into a common platform. WellRyde provides solutions in the NEMT transportation, K-12, rural transit and demand response. Since its inception in 2015, as a specialized people movement platform, WellRyde has consistently focused on ease of use, ease of deployment, rider engagement and visibility. Combined with its capability of package movement, inherited from nuDeliverIt, WellRyde today is capable of delivering care solutions such as prescription delivery, hospital/clinic supply, nurse visits, day care center visits under the broad umbrella of Non-Emergency Medical Services (NEMS). The HIPAA-compliant platform built on next gen micro-services architecture is poised for rapid growth and expansion and can support over 100 million trips a year. For more information on WellRyde please visit https://www.wellryde.com.

nuVizz Marketplace helps consolidate delivery & transportation demand and supply to create new opportunities for shippers/trip sources and carriers/transportation providers. nuVizz MarketPlace is a transportation network wide program and comes close on the heels of TripMarket that today boasts of nearly 2 million trips a year.

The nuVizz platform hosts more than 2000 companies, 35000+ drivers and supported more than 50 million transactions in 2019 on its SaaS platform. For more information, please visit http://www.nuvizz.com, http://www.nudeliverit.com, http://www.wellryde.com.

Contact: Veda Ramachandran

Vice President, Customer Success

veda@wellryde.com

sales@nuvizz.com

info@wellryde.com

Share article on social media or email:

eClinical Solutions Teams with Karyopharm for COVID-19 Treatment Trial


“The eClinical Solutions team is extremely motivated by the opportunity to contribute to finding new therapies that may treat COVID-19,” said Raj Indupuri, CEO of eClinical Solutions. “We are proud to partner with Karyopharm to support rapid data collection, cleaning and review for this program.”

eClinical Solutions LLC, a leading global provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) on randomized clinical trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study of an XPO1 inhibitor in patients with severe viral infections. XPO1 inhibitors like selinexor (marketed as XPOVIO®) have previously shown preclinical activity against respiratory viruses, including SARS-CoV.

“The eClinical Solutions team is extremely motivated by the opportunity to contribute to finding new therapies that may treat COVID-19,” said Raj Indupuri, CEO of eClinical Solutions. “We are proud to partner with Karyopharm to support rapid data collection, cleaning and review for this program. The way they use modern technologies in clinical research to optimize data collection and analysis demonstrates their dedication to innovation not only in scientific research, but throughout the clinical development process.”

The eClinical Solutions Data Services team configured the data capture system for the trial using Medidata Rave EDC and the elluminate Clinical Data Platform for agile data management and review. The Karyopharm and eClinical Solutions teams collaborated closely to build a fully validated data database to collect data from physicians and patients in just 15 days—an accelerated timeline in order to meet the first patient milestone of this critical research initiative. The eClinical Solutions data management team is using elluminate Data Central to support data review activities for the study to ensure data is rapidly cleaned and available for medical and safety review.

“eClinical Solutions has been a valuable partner on other selinexor research programs. Their team’s knowledge of Karyopharm data standards and processes combined with their expertise in data collection platforms and clinical data management practices helped us meet our accelerated timelines for this important new research,” said Kristan Gallitano, SVP Development Operations at Karyopharm Therapeutics.

About eClinical Solutions

eClinical Solutions is a leading global provider of cloud-based enterprise software and software-driven clinical data services. The elluminate® platform provides life sciences companies with greater control of their clinical trial data. elluminate software and data-driven services have been used by more than 100 life sciences companies on more than 1000 trials. eClinical Solutions has worked with Karyopharm since 2015 to tech-enable a simplified data flow and help produce high quality data for more than 10 studies, including 5 database locks that provided the data for the July 2019 FDA approval of Karyopharm’s lead compound XPOVIO® (selinexor). Learn more about eClinical Solutions and Karyopharm in this Case Study. For more information visit eclinicalsol.com.

About Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit http://www.karyopharm.com.

Share article on social media or email:

CQ fluency, Corporate Plus 2020 Inducted by National Minority Supplier Development Council


CQ fluency was inducted as a National Minority Supplier Development Council (NMSDC) official Corporate Plus® member with supporting sponsorship from Anthem. The NMSDC Corporate Plus program is an ‘unprecedented’ program for minority businesses of the ‘highest caliber’, raising the prominence of minority businesses across America. The Corporate Plus program was established to facilitate requests from corporate members to bridge connections with minority suppliers.

CQ fluency is a certified minority-owned business (MBE) by the NMSDC since 2009. President and CEO of CQ fluency, Elisabete Miranda, is a former board member as well as a former MBEIC Committee Co-Chair. As an MBE, CQ fluency is part of a powerful network of minority businesses directly impacting economic growth in the United States.

The Corporate Plus® status acknowledges CQ fluency’s proven capacity to fulfill national contracts and underscores a commitment to diversity by proactively identifying and building relationships with certified small and minority owned businesses. Upon award of membership, Elisabete said, “I can’t begin to tell you how grateful I am that CQ fluency is now part of an elite group of MBEs (less than 100) that help raise the level and perception of minority businesses to national prominence in corporate America, especially now when minority support is so critically important. ” Elisabete continued, “All of us at CQ fluency thank NMSDC for the recognition and Anthem not only for the nomination but also for being such an important client of ours for several years.”

About CQ fluency:

CQ fluency is a language services company that specializes in culturally relevant translations for life science and healthcare in over 170 languages. We translate meaning and feeling of messages to facilitate real connections and true cultural understanding between people who don’t speak the same language. More about CQ fluency can be found on our website at http://www.CQfluency.com.

About NMSDC:

The National Minority Supplier Development Council, Inc. established in 1973, is a vital link between major corporations and minority business enterprises (MBEs). Each year, member corporations have reported billions of dollars spent with Council- certified Minority Business Enterprises. Serving the United States, The Council is one of the 23 regional affiliates of the National Minority Supplier Development Council, Inc. for more information about NMSDC visit http://www.nmsdc.org

Share article on social media or email:

DuPont Achieves Non-GMO Certification for SeaGel®, Reinforces Commitment to Sustainable, Quality Ingredients


News Image

“As consumers become more informed about what goes into their daily supplements, they’re searching for products that are natural, sustainable and non-GMO,” said Michael Baumann, global strategic marketing manager, DuPont Nutrition & Biosciences

Among consumers, the Non-GMO Project Verified seal is the most trusted non-GMO label, providing assurance that the product has completed a rigorous, unbiased evaluation for compliance with the Non-GMO Project Standard. Drug and dietary supplement manufacturers can now turn to DuPont Nutrition & Biosciences to bring that seal to their end-use soft capsule products.

After scrupulous testing of raw material sourcing and manufacturing, SeaGel® CAP101 and SeaGel® CAP203 non-animal soft capsule technologies achieved Non-GMO Project Verified certification, reinforcing DuPont’s commitment to providing safe, sustainable ingredients that meet industry demand.

SeaGel® offers a plant-based alternative to traditional soft capsules. While soft capsules are one of the most common delivery formats for active ingredients, they are traditionally made with gelatin. Naturally derived from seaweed, SeaGel® is animal-free, making it inclusive to vegan, vegetarian, Halal and Kosher diets. Its recent non-GMO designation allows manufacturers incorporating SeaGel® into their formulation to appeal to a wider range of consumers.

“As consumers become more informed about what goes into their daily supplements, they’re searching for products that are natural, sustainable and non-GMO,” said Michael Baumann, global strategic marketing manager, DuPont Nutrition & Biosciences. “Adding the iconic non-GMO butterfly to their end products helps manufacturers and brand owners provide customers with immediate assurance that a product aligns with their lifestyle needs.”

SeaGel® offers manufacturers solutions to a wide range of formulation challenges, and when compared to alternative vegetarian soft capsule technology, it provides superior sealing performance and reduced leakage. Since seaweed has a higher melting point than gelatin, SeaGel® soft capsules are more heat stable, ensuring they will not become sticky or melt together inside capsule bottles. Its adaptability to shape, color and coating—plus easy incorporation into existing gelatin manufacturing operations—allows for a wide range of brand strategies with minimum capital investment.

“The dietary supplement market is growing rapidly, with 4,000 new products introduced each year in the U.S. alone,” said Benjamin Roscoe, application development & innovation manager, DuPont Nutrition & Biosciences. “By consistently evolving alongside our customers, we’re empowering them to differentiate from competitors and meet consumer demand with safe, natural and sustainably sourced ingredients.”

As North America’s only third-party non-GMO verification program, the Non-GMO Project’s verification continues to set the industry standard for non-GMO food, drug and beauty products. To achieve qualification, suppliers must first pass a rigorous product evaluation which includes a review of raw material sources, manufacturing practices and finished products to prevent contamination by genetically modified organisms (GMOs).

In achieving the recent certification, DuPont confirms its commitment to thorough and precise specifications, quality ingredients and sustainable practices, enabling manufacturers and brand owners to be transparent about ingredient sourcing and manufacturing processes. Ultimately this leads to increased consumer satisfaction and trust.

To learn more about SeaGel® and DuPont’s extensive product portfolio, please visit pharma.dupont.com/pharmaceutical-brands/seagel.html

1. https://www.consumerreports.org/cro/2014/10/where-gmos-hide-in-your-food/index.htm

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com or http://www.biosciences.dupont.com

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com.

# # #

06/24//2020

DuPont™, the DuPont Oval Logo, XIVIA® and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Lindsay Torriero                

+1 407 701 2133                

Lindsay.Torriero@dupont.com

Reena Chaudhary

+91 9769820494

Reena.Chaudhary@dupont.com

Share article on social media or email:

Safe Boating Campaign Reminds Boaters to Boat Sober this Fourth of July


Choose to boat sober this Fourth of July.

Choose to boat sober this Fourth of July.

“Operating a boat – or even being a passenger – is incredibly risky while under the influence of alcohol or drugs.” – Peg Phillips, Executive Director, National Safe Boating Council

The Safe Boating Campaign, a worldwide effort focused on responsible boating, reminds boaters to boat sober this Fourth of July. Boating under the influence, or BUI, is the leading contributing factor in recreational boater deaths, according to the U.S. Coast Guard.

“The July 4 holiday is around the corner, and unfortunately has become known for drinking and boating, and deadly accidents,” said Peg Phillips, executive director of the National Safe Boating Council, and lead organization for the Safe Boating Campaign.

“Operating a boat – or even being a passenger – is incredibly risky while under the influence of alcohol or drugs,” continued Phillips. “Drunken passengers can easily fall overboard, swim near the propeller, lean over the side, or stand up in small boats causing the boat to capsize.”

The side effects of alcohol or drug use, such as impaired judgment, reduced balance and poor coordination, are magnified while boating, due to environmental conditions from the sun, wind and boat motion.

“Impairment can be even more dangerous for boaters, since most have less experience and confidence operating a boat than they do driving a car,” said Yvonne Pentz, communications director of the National Safe Boating Council. “Boaters should also always wear a life jacket, similar to wearing a seat belt when you’re in a vehicle.”

The National Association of State Boating Law Administrators, a partner of the Safe Boating Campaign, in collaboration with the U.S. Coast Guard and law enforcement agencies nationwide, is coordinating the annual Operation Dry Water three-day weekend. This heightened BUI awareness and enforcement effort will be held from July 3 to July 5 in every U.S. state and territory.

Since the inception of the Operation Dry Water Campaign in 2009, law enforcement officers have removed 4,095 BUI operators from the nation’s waterways and made contact with over 1.5 million boaters during the annual three-day weekend.

The Safe Boating Campaign is produced under a grant from the Sports Fish Restoration and Boating Trust Fund and administered by the U.S. Coast Guard. For more information and to follow the campaign on social media, please visit https://safeboatingcampaign.com/.

Share article on social media or email:

American College of Lifestyle Medicine Announces Shift of 2020 Annual Conference to a Live Virtual Format to be Held October 22-25


News Image

“Our content will explore how Lifestyle Medicine plays a critical role in strengthening resilience and reducing vulnerabilities.”

The American College of Lifestyle Medicine today announced that its 2020 Lifestyle Medicine Annual Conference, originally scheduled for Nov. 1-4 in Carlsbad, CA, will now be held as a live, virtual event, Thursday through Sunday, October 22-25, 2020.

Conference registration includes 20 hours of both live and recorded Lifestyle Medicine-related presentations, with an option to participate in an additional eight hours of interactive pre- and post-conference workshops. The conference has been approved for AMA PRA Category 1 Credit™.

Registration for the new virtual event, with the theme “Lifestyle Medicine: Health Restored,” is now open. A full agenda and additional details can be found at https://lifestylemedicineconference.org/

“After thoughtful deliberation, and with the utmost concern for the health and safety of all our constituents, our Board unanimously voted for this change,” said ACLM President Dexter Shurney, MD, MBA, MPH, FACLM, dipABLM. “We are excited that, with this change, even more medical professionals and trainees will have the opportunity to be part of this online medical education experience, showcasing the foremost experts in our field, with evidence-based presentations on food and exercise as medicine, to sleep, social connection, and the other pillars of Lifestyle Medicine.”

LM2020 will open with Legends of Lifestyle Medicine and Their Prescription to the World’s Most Pressing Health Crises, featuring Drs. Dean Ornish, Caldwell Esselstyn, T. Colin Campbell and John McDougall, all of whom are previous recipients of ACLM’s Lifetime Achievement Award. Other notable sessions include Dr. Roy Taylor’s presentation, Averting the Looming Global Pandemic of Type 2 Diabetes: Understanding T2D from the DiRECT, Counterpoint and Counterbalance Research Studies, and ACLM President Dexter Shurney leading an expert panel focused on Lifestyle Medicine: A Health Disparities Solution.

“The new dates in October will offer live sessions with the same scientific rigor and educational experience our annual conference attendees have come to expect,” said 2020 Conference Planning Committee Chair Sami Beg, MD, MPA, MPH, FACLM. “The focus of our content will explore how Lifestyle Medicine plays a critical role in strengthening resilience and reducing vulnerabilities. By treating the root cause of chronic disease, we set a solid foundation for restoring health throughout the nation and around the world.”

Conference registration is set at $599 for ACLM Members, $749 for Non-Members. Student registration is $49 for Members and $99 for Non-Members, with an abundance of student and trainee scholarship opportunities.

The American Board of Lifestyle Medicine (ABLM) certification exam, traditionally hosted immediately following the annual conference, will be offered in 2020 as a “take-from-home” exam November 7-8. Attendance at the virtual conference will fulfill the “live” CME prerequisite for the 2020 ABLM exam. The deadline to register on the ABLM website is September 30, 2020.

“This is an unprecedented time, but out of crisis comes opportunity,” Shurney said. “The events of this year have made the field ACLM represents all the more relevant, with the nation and world awakening to the urgent need for Lifestyle Medicine to become the foundation of health care. Health restoration is what our world needs and what Lifestyle Medicine delivers.”

The 2020 conference is presented by The Prospect Fund, a socially responsible investment fund which offers its resources to advance important causes globally.

ABOUT THE AMERICAN COLLEGE OF LIFESTYLE MEDICINE: ACLM is the medical professional society for those dedicated to the advancement and clinical practice of Lifestyle Medicine as the foundation of a transformed and sustainable health care system. Lifestyle Medicine is the use of a whole food, plant-predominant dietary lifestyle, regular physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connection as a primary therapeutic modality for treatment and reversal of chronic disease.

More than a professional association, ACLM is a galvanized force for change. ACLM addresses the need for quality education and certification, supporting its members in their individual practices and in their collective mission to domestically and globally promote Lifestyle Medicine as the first treatment option, as opposed to a first option of treating symptoms and consequences with expensive, ever increasing quantities of pills and procedures. ACLM members are united in their desire to identify and eradicate the root cause of disease. Learn more at http://www.LifestyleMedicine.org.

Share article on social media or email: